Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 23 May 2024Expected publication date: 21 August 2024
Selpercatinib for treating advanced thyroid cancer with RET alterations (MA review of TA742) [ID6288]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024